Latest Updates
Read the latest news that impacts the oncology community.
- Published On: August 27th, 2024
Managers of the Oregon State Employee Plan learned something after the state capped hospital prices and the plan used the projected savings to lower plan participants' out-of-pocket costs: Lowering the out-of-pocket costs increased the amount of care the participants used.
- Published On: August 26th, 2024
IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) announced today that it signed a definitive agreement to acquire a controlling interest in Community Oncology Revitalization Enterprise Ventures, LLC (Core Ventures). Core Ventures, a business and administrative services organization, was established by Florida Cancer Specialists & Research Institute, LLC (FCS), a leading physician-owned community oncology practice. FCS physicians will continue to retain a minority interest in Core Ventures.
- Published On: August 26th, 2024
Johnson & Johnson is opening a new front in the pharmaceutical industry’s fight against lucrative drug discounts for hospitals.
- Published On: August 26th, 2024
Johnson & Johnson is proposing major changes to the way certain hospitals procure two of its biggest selling products under the 340B drug pricing program—but the federal government is pushing back.
- Published On: August 26th, 2024
State lawmakers' attempt to hear explanations of rising prescription drug costs on patients and pharmacies turned into a heated exchange Wednesday between pharmacists, legislators and the middlemen who set procurement and sale prices for drugs sold to patients.
- Published On: August 26th, 2024
The launch of Mark Cuban's online pharmacy ignited a much-needed discussion about transparency and affordability in the pharmaceutical industry.
- Published On: August 26th, 2024
HOUSTON COUNTY, Ga. — Houston Healthcare’s recent partnership with Emory Healthcare has sparked both anticipation and concern in Central Georgia.
- Published On: August 23rd, 2024
Among 196,766 commercially insured and Medicare Advantage patients who newly initiated biologic drugs with available biosimilar versions, biosimilar initiation increased from 1 percent in 2013 to 34 percent in 2022.
- Published On: August 23rd, 2024
Biosimilar drugs—lower-cost alternatives to expensive biologic drugs—have the potential to slow the growth of US drug spending.
- Published On: August 23rd, 2024
A federal judge's ruling this week that blocked the Federal Trade Commission's near-total ban on noncompete clauses in employment contracts is creating more uncertainty for healthcare employers as they await the agency's next move.